Damion Nero, PhD

This study suggests that lower healthcare resource use and achieving low disease activity are associated with first-line abatacept compared with a first-line tumor necrosis factor-α inhibitor for patients with early rapidly progressive rheumatoid arthritis.

This retrospective cohort study in a Medicare Advantage population posits that type 2 diabetes mellitus complications pose an excess burden on healthcare resource use and related costs.